NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Lifecore Biomedical, Inc. (LFCR) Stock Analysis

Lifecore Biomedical, Inc. (LFCR) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

LFCR

$4.40

+$0.05 (+1.15%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LFCR with… →

LFCR Key Statistics

As of Sep 4, 2026
Trading
Open
$4.35
Previous Close
$4.35
Day's Range
4.29–4.60
52-Week Range
3.63–8.98
Volume
277.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.08
Valuation
Market Cap
$166.55M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.66
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.29
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.28
Financials (FY)
Revenue (FY)
$128.87M+0.47%
Net Income (FY)
−$38.72M−422.29%
Profit marginThe share of revenue left as profit after all costs and taxes.
−23.78%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.85M
1-Year Return
−44.58%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
167.71K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LFCR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.21%
2025+10.09%
2024+20.03%
2023−4.48%
2022−41.62%
2021+2.30%
2020−4.07%
2019−4.48%
2018−6.03%
2017−8.70%
2016 (partial year)+13.21%

As of September 4, 2026.

LFCR Revenue and Earnings by Fiscal Year

FY ends May
Fiscal yearRevenueNet incomeNet margin
2024$128.87M−$38.72M−30.0%
2023$128.26M$12.01M9.4%
2022$103.27M−$99.56M−96.4%
2021$111.27M−$116.72M−104.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$128.87M$40.30M−$12.01M−$38.72M−30.0%
2023$128.26M$41.85M−$7.19M$12.01M9.4%
2022$103.27M$27.99M−$19.72M−$99.56M−96.4%
2021$111.27M$39.07M−$3.43M−$116.72M−104.9%

Annual figures as reported, in the company's reporting currency. As of May 31, 2025.

LFCR Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricLFCRDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.292.3044% below
Profit margin−23.78%−3.14%20.6 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Lifecore Biomedical, Inc. (LFCR) at $166.55M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 382 employees.

The most recent close on file for LFCR is $4.40, dated September 4, 2026. That is +$0.05 (+1.15%) against the previous close. Over the past 52 weeks the price has ranged from $3.63 to $8.98. The latest close sits 21.21% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to $128.87M. Against the prior fiscal year total of $128.26M, that is a change of +0.47%. The same year closed with a net loss of $38.72M. Profit margin runs at −23.78%. That is 20.6 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −1.28.

Across the 4 fiscal years on file, revenue moves from $111.27M in 2021 to $128.87M in 2024. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.66. Measured against sales, the shares trade at 1.29 times revenue. On price-to-sales that is 43.98% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned −44.58%. Across 10 years the annualized return works out at −10.25%. Beta against the wider market is reported at 1.09. Annualized volatility over the trailing 10 years is 63.19%.

Growth & Income

No dividend is on file for LFCR.

2026 is still running; the price is −46.21% year to date. The strongest complete calendar year on file is 2024 at +20.03%; the weakest is 2022 at −41.62%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Lifecore Biomedical, Inc. (LFCR) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lifecore Biomedical, Inc. LFCR $166.55M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Lifecore Biomedical, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Visit website →